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Abstract
Background: Controversy exists about the optimal management of a patent ductus arteriosus (PDA) in preterm
infants. A persistent PDA is associated with neonatal mortality and morbidity, but causality remains unproven.
Although both pharmacological and/or surgical treatment are effective in PDA closure, this has not resulted in an
improved neonatal outcome. In most preterm infants, a PDA will eventually close spontaneously, hence PDA
treatment potentially increases the risk of iatrogenic adverse effects. Therefore, expectant management is gaining
interest, even in the absence of convincing evidence to support this strategy.
Methods/design: The BeNeDuctus trial is a multicentre, randomised, non-inferiority trial assessing early
pharmacological treatment (24–72 h postnatal age) with ibuprofen versus expectant management of PDA in
preterm infants in Europe. Preterm infants with a gestational age of less than 28 weeks and an echocardiographic-
confirmed PDA with a transductal diameter of > 1.5 mm are randomly allocated to early pharmacological treatment
with ibuprofen or expectant management after parental informed consent.
The primary outcome measure is the composite outcome of mortality, and/or necrotizing enterocolitis Bell stage ≥
IIa, and/or bronchopulmonary dysplasia, all established at a postmenstrual age of 36 weeks. Secondary short-term
outcomes are comorbidity and adverse events assessed during hospitalization and long-term neurodevelopmental
outcome assessed at a corrected age of 2 years. This statistical analysis plan focusses on the short-term outcome
and is written and submitted without knowledge of the data.
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Background
A patent ductus arteriosus (PDA) is common in preterm
infants [1] and is associated with neonatal mortality and
morbidity, such as bronchopulmonary dysplasia (BPD),
necrotizing enterocolitis (NEC) and intraventricular
haemorrhage (IVH). Controversy exists about its optimal
management, as early PDA treatment induces PDA clos-
ure but does not improve overall outcome [2–4].
Ductus arteriosus closure is delayed in prematurity,
since it is not yet programmed for prompt postnatal
closure [5]. This is supported by the observation of a
high amount of spontaneous closure [6] even after
‘failed’ pharmacological treatment [7]. Since early
pharmacological treatment has not been proven to im-
prove outcome, it potentially increases the risk of iatro-
genic adverse effect in patients in whom the PDA would
have closed spontaneously. These observations have led
to an increased interest in expectant PDA management
[8]. Evidence to support expectant PDA management is
scarce and conflicting [9], due to a high amount of open
label treatment in placebo-controlled randomised con-
trolled trials (RCTs) [4, 10] and a heterogeneous defin-
ition of (haemodynamic significant) PDA [11].
The BeNeDuctus trial assesses early pharmacological
treatment within 24–72 h postnatal age (PNA) with ibu-
profen versus expectant management of PDA in preterm
infants in Europe. The study protocol was published pre-
viously [10]. This paper describes the statistical analysis
plan (SAP) for short-term outcomes in detail, which is
written and submitted without knowledge of the data.
Objectives
The primary aim of the BeNeDuctus trial is to investi-
gate whether an expectant management is non-inferior
to early treatment (24–72 h PNA) for PDA (diameter >
1.5mm) in preterm infants, born at a gestational age less
than 28 weeks, with regard to the composite outcome of
mortality and/or NEC (Bell stage ≥ IIa) and/or BPD at a
postmenstrual age (PMA) of 36 weeks.
Methods/design
Design and setting
The BeNeDuctus trial is a multicentre, non-inferiority
trial in preterm infants with an echocardiographic-
confirmed PDA > 1.5 mm before 72 h of PNA. Patients
are recruited from 17 neonatal intensive care units
(NICUs) in the Netherlands, Belgium and Denmark.
Study protocol development and conduct
The BeNeDuctus trial is registered with the Dutch Trial
Register NTR5479 (registered on 19 October 2015), the
registry sponsored by the United States National Library
of Medicine Clinicaltrials.gov NCT02884219 (registered
May 2016) and the European Clinical Trials Database
EudraCT 2017-001376-28. This study has been approved
by the medical ethics committee of the Radboud Univer-
sity (CMO Arnhem-Nijmegen; Number 2016-2552/
NL57885.091.16). The local ethics committee of each
participating hospital approved the local feasibility of the
study protocol.
During the course of the study the ethics committee
approved two amendments. On 25 September 2017, the
study protocol was adapted for use by participating sites
outside The Netherlands, the data monitoring plan was
updated and cyclo-oxygenase inhibitor (i.e. indometh-
acin and/or ibuprofen) was changed to ibuprofen due to
unavailability of indomethacin. On 26 February 2018, re-
imbursement of investigational medicinal product in
Belgium was added and the Data Safety Monitoring
Board (DSMB) paragraph was edited according to an up-
dated DSMB charter.
The trial is conducted according to the principles of
the Declaration of Helsinki [12], good clinical practice
guidelines and Dutch, Belgian and Danish legislation re-
garding medical research involving human subjects [13].
Informed consent from both parents needs to be ob-
tained before patients can be randomised in the trial.
An independent DSMB monitors the progress of the
study and performs interim-analysis on safety. The trial
will be reported according to the Consolidated Standards
of Reporting Trials (CONSORT) guidelines [14].
In- and exclusion criteria are described in detail in the
previously published study protocol [10]. In summary,
preterm infants born at a gestational age of less than 28
weeks with an echocardiographic-confirmed PDA with a
diameter > 1.5 mm and transductal (predominantly) left-
to-right shunting at a PNA of less than 72 h are eligible.
Included patients are randomised to either early
pharmacological treatment with ibuprofen, dosage ac-
cording to local protocol or expectant management. The
use of ‘open-label’ pharmacological treatment in the
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expectant management group is most definitely discour-
aged and only allowed when predefined open-label treat-
ment criteria are met [10]. In a strict sense open-label
treatment is a misnomer, since in this non-placebo con-
trolled nor blinded clinical trial, no label could be
opened in the expectant management study group. Due
to the widespread use of the term open label in PDA re-
search, we will continue to use this term for pharmaco-
logical treatment in the expectant treatment group.
Randomisation and data collection
Eligible patients are randomly allocated to early pharma-
cological treatment or expectant management per centre
and stratified according to gestational age in two strata
(stratum A less than 260/7 weeks’ gestation or stratum B
260/7–276/7 weeks’ gestation). Stratification per centre
was done for pragmatic reasons and is not likely to influ-
ence the primary outcome. Therefore, the analyses will
not be adjusted for centre. In an additional analysis, the
primary outcome will be adjusted for gestational age, as
this is a prognostic covariate, using Poisson regression.
Block size varies from four to eight. Multiple birth in-
fants are preferably randomised independently, unless
there is an explicit request from the parents to expose
all siblings to the same treatment group as the first pa-
tient is allocated to. The randomisation process is cen-
trally controlled and web-based.
Data management is implemented according to good
clinical practice guidelines. Patient data, both until hos-
pital discharge and long-term follow-up data, are entered
via an electronic case record form in a central web-
based Castor® Database to facilitate on-site data entry
[15]. The most important data is shown in Table 1 for
baseline characteristics and Table 2 for outcome
measures.
Primary outcome
The primary outcome is the dichotomous composite
outcome of mortality, and/or NEC (Bell stage ≥ IIa) [16],
and/or BPD at a PMA of 36 weeks. BPD is defined as
the need for supplemental oxygen or positive pressure
ventilatory support at a PMA of 36 weeks and diagnosed
following international standard criteria by Bancalari
[17], including an oxygen reduction test according to
Walsh [18] (Table 2).
Short-term secondary outcomes
Secondary outcomes are adverse events till discharge,
which are shown in Table 2.
Short-term secondary outcome definitions
Hyperlactataemia is defined as a serum concentration >
2.5 mmol/L, either capillary or arterial [19]. Renal failure
is defined as creatinine > 120 μmol/L or urine output <
0.5 ml/kg/h. Hypertension is defined as mean arterial
blood pressure > 95th percentile, according to Zubrow
or Dionne [20, 21].
Respiratory support is divided in invasive, encom-
passing conventional and high-frequency ventilation,
and non-invasive, encompassing non-invasive positive
pressure ventilation, nasal continuous positive airway
pressure and high-flow nasal cannula therapy. High-
flow nasal cannula therapy is defined as a flow > 1 l
per minute. Low flow, defined as flow < 1 l per mi-
nute, is considered as respiratory support for supple-
mental oxygen. Pulmonary air leakage is defined as
pneumothorax, pulmonary interstitial emphysema or
pneumomediastinum.
IVH is graded according to Volpe [22]. Periventricular
echogenicity is graded according to Hashimoto [23].
Time to full enteral feeding is defined as the first mo-
ment full enteral feeding is reached, even in cases in
which enteral feeding needs to be stopped afterwards,
for example due to NEC.
Sepsis is defined as positive blood culture and need for
antibiotics. Meningitis is defined as sepsis with antibiotic
treatment regimen (dosage and duration) for meningitis,
irrespective of spinal fluid culture. Thrombocytopenia is
defined as a platelet count < 100 x 109/L. Hypergly-
caemia is defined as elevated glucose level necessitating
insulin treatment according to local protocol.
Retinopathy of prematurity (ROP) is graded according
to the international classification [24].
Long-term secondary outcomes
Neurodevelopmental outcome is assessed in all Dutch
and Belgian children in the National Neonatal Follow
Up Program at a corrected age of 24 months by (a)
paediatric and neurologic examination; (b) cognitive as-
sessment with Bayley Scales of Infant and Toddler De-
velopment, Third Dutch Edition (BSID-III-NL); (c)
behavioural assessment with Child Behaviour Check List
(CBCL), Teacher Report Form (TRF) questionnaire. Des-
pite the Movement Assessment Battery for Children,
Second Dutch Edition (Movement ABC 2-NL) was men-
tioned in the study protocol, this will not be included in
the neurodevelopmental outcome at 24 months cor-
rected age as it is assessed at five years corrected age.
Motor scales of the BSID-III-NL will be used to assess
motor function. Equivalent assessments may be used for
non-Dutch or Belgian children.
Long-term secondary outcome definitions
Participants who are alive and have a BSID III cognitive
and motor composite score at 2 years corrected age ≥ 85
(−1 standard deviation) will be defined as having sur-
vived without neurodevelopmental impairment.
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General health is considered (a) good, i.e. no readmis-
sions in first 2 years after discharge home; (b) moderate,
i.e. 1–3 readmissions; or (c) poor, i.e. >3 readmissions.
Neurologic examination is subdivided in (a) normal,
i.e. no symptoms of pathology; (b) mild abnormal, i.e.
mild muscle tone abnormalities and coordination prob-
lems that do not hamper functioning and/or develop-
ment; and (c) abnormal, i.e. muscle tone abnormalities
and/or coordination problems that are hampering devel-
opment, cerebral palsy and/or infantile encephalopathy.
Vision is scored as (a) normal, i.e. no problems with
sight; (b) mildly abnormal, i.e. treated by ophthalmolo-
gist/orthoptist for abbreviation (goggles) or strabismus/
amblyopia; (c) abnormal, i.e. limited vision, but ability to
see anything; and (d) severely abnormal, i.e. blind.
Hearing is scored as (a) normal, i.e. no hearing prob-
lems; (b) mildly abnormal, i.e. light hearing loss for
which control or treatment; (c) abnormal, i.e. neurosen-
sory hearing loss (partially) corrected with hearing aid;
and (d) severely abnormal, i.e. neurosensory hearing loss,
deafness.
Adverse events (AEs) and serious adverse events (SAE)
As this trial is undertaken in a fragile patient group,
context-specific (S)AEs are not individually reported to
the medical ethics committee, as described in the study
Table 1 Baseline maternal and patient characteristics of randomised patients
Early pharmacological treatment (n= ) Expectant management (n= )





























Data is presented as mean (± standard deviation) or median [interquartile ranges]. Categorical variables are presented as counts (percentage)
ACS antenatal corticosteroids, HELLP haemolysis, elevated liver enzymes and low platelets, PDA patent ductus arteriosus, PPROM preterm premature rupture of
membranes, NSAIDs non-steroidal anti-inflammatory drugs, TTN transient tachypnea of the newborn
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Secondary outcomes
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Surgical PDA ligation





Death Mortality at 28 days PNA









Pulmonary BPD at 28 days PNA













GI NEC (Bell stage ≥ IIa)
Gastrointestinal haemorrhage
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protocol [10, 25, 26]. Non-context specific (S)AEs are re-
ported to the medical ethics committee and will be
listed.
Statistical methods specified in the study protocol
Sample size calculation
As described in the study protocol, the a priori risk of
mortality, NEC and BPD is estimated to be 20%, 10%
and 15%, respectively, for preterm infants born at a ges-
tational age of less than 28 weeks, based on data from
The Netherlands Perinatal Registry (PRN foundation) in
the period 2008–2012. Non-inferiority is defined as a
significant difference in the primary outcome parameter
between the two groups of less than 10%. In other
words, the one-side 95% confidence interval of the ob-
served difference between an expectative approach and
ibuprofen treatment should not exceed the non-
inferiority margin of 10%.
With an estimated a priori risk for the composite of
mortality and/or NEC and/or BPD at 36 weeks PMA
of 35%, a one-sided type I error of 5% and a power
of 80%, the sample size to exclude a non-inferiority
margin of 10% for the difference of proportion of
participants reaching the primary outcome parameter
is 564 patients, being 282 patients in each group. This
sample size is calculated using PASS 2008, version
08.0.8 NCSS.
Original proposed analyses
The originally proposed analyses are described in the
published study protocol [10]. For the primary outcome,
a 95% one-sided confidence interval for the risk differ-
ence will be calculated, and when based on this interval,
a difference of 10% or more can be excluded, non-
inferiority will be concluded.
Treatment effects for the dichotomous clinical out-
comes will be reported using risk differences with 95%
confidence interval. Normally distributed data will be
presented as mean ± standard deviations, uneven distrib-
uted data as medians with interquartile ranges. Categor-
ical data will be analysed using the chi-square for two
and multiway tables. Continuous data will be analysed
using the Student’s t test. Both intention-to-treat and
per-protocol analyses will be employed. Statistical sig-
nificance is defined as a p value < 0.05. Here, we present
our final and further detailed SAP.
Interim analyses and safety reporting
To protect patients and to assist and advise the principal
investigator in protecting the safety, validity and credibil-
ity of the trial, a DSMB is installed. The DSMB consists
of a neonatologist, paediatric cardiologist and biostatisti-
cian. The members have no competing interests and are
not involved in the trial. Their composition, tasks, re-
sponsibilities and working procedures are described in a
charter (available on request).




















Length of hospitalisation [days]
DA closed at discharge
All outcome measures are till hospital discharge to home unless otherwise specified. Data is presented as mean (± standard deviation) or median [interquartile
ranges]. Categorical variables are presented as counts (percentage)
BPD bronchopulmonary dysplasia, CNS central nervous system, COXi cyclo-oxygenase inhibitor, DA ductus arteriosus, DOL day of life, GI gastrointestinal, IVH
intraventricular haemorrhage, LF low-flow, MV mechanical ventilation, NEC necrotizing enterocolitis, PDA patent ductus arteriosus, PHVD posthemorrhagic
ventricular dilatation, PMA postmenstrual age, PNA postnatal age, PVE periventricular echogenicity, ROP retinopathy of prematurity, Rx pharmacological treatment,
SIP spontaneous gastrointestinal perforation
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Safety analysis is scheduled when 15%, 30%, 50% and
75% of the data are gathered. Before every interim analysis
the DSMB receives a report from the trial coordinator and
data manager, that includes data on (1) context-specific
(S)AEs, subdivided in (a) hemodynamic, (b) pulmonary,
(c) central nervous system, (d) gastrointestinal, (e) infec-
tious, (f) renal, (g) ophthalmologic, (h) metabolic and (i)
mortality; (2) non-context-specific (S)AEs; and (3) open-
label treatment in expectant study group.
The DSMB charter states that there are two possible
reasons for stopping the trial early, namely concerns for
safety and futility. In principle, the trial will not be
stopped early before the minimum number of evaluable
patients required (n = 564) are included for beneficial ef-
fect of ibuprofen treatment on the primary outcome.




As described above the first phase of data analysis and
reporting will include all outcome data up to discharge
to home. Analyses will start once all data to discharge of
the last included patient have been obtained, the data-
base has been checked and locked and this SAP has been
submitted for publication. The analyses will be per-
formed by TH, WdB and RD.
Intention-to-treat analysis will be performed. Since
open-label treatment might have an effect on both PDA
closure and might be associated with adverse events,
analyses will also be done in a per-protocol population
as described in detail below. For all relevant parameters,
outcome with 95% confidence intervals will be pre-
sented. A p value < 0.05 will be considered statistically
significant. For the primary analysis, no adjustment for
multiple testing will be applied. The secondary analyses
are to be considered as exploratory. For statistical pro-
gramming and analysis, we will use SPSS version 25.0
(IBM Corp. 2017) and the R environment for statistical
computing (R Foundation for Statistical Computing,
Vienna, Austria).
The short-term outcome analyses will be performed
and published before the assessment of the long-term
outcomes at 2 years of corrected age of all patients have
been completed, since it is considered unethical by the
neonatal community to withhold the results of the pri-
mary and short-term secondary outcomes for another 2
years. In the second phase, the neurodevelopmental out-
comes after 2 years will be analysed, reported and pub-
lished afterwards.
Withdrawal
As stated in the study protocol [10], the investigator or
attending physician can decide to withdraw a subject
from the study for urgent medical reasons. If they wish,
parents or caregivers can withdraw their consent for the
study at any time for any reason. Patients in the expect-
ant management arm that meet the open-label criteria
and patients in the early pharmacological treatment arm
that meet the surgical ligation criteria will remain in fol-
low up and are therefore not withdrawn from the study,
as are patients that develop contraindications for con-
tinuation of ibuprofen (Fig. 2). Other reasons for with-
drawal will be presented as supplementary material with
reason and count per treatment group.
Handling of missing data
To minimize the amount of missing data, multiple at-
tempts will be undertaken to retrieve data. Both level III
and II (referral) hospitals will be contacted, since most
patients will be transferred to referral hospitals after the
initial hospitalization. As the primary outcome will be
assessed at a PMA of 36 weeks, so generally before dis-
charge to home, we anticipate minimal missing values.
Missing data till discharge will therefore not be imputed.
For the long-term outcome at 2 years of corrected age,
a higher amount of missing data is expected due to loss
to follow up. In case of loss to follow-up the reason for
this will be recorded. Their available trial results and
characteristics will be analysed and sensitivity analyses
will be performed as described later.
Definition of analysis sets
Intention-to-treat population
The intention-to-treat population consists of all rando-
mised infants, regardless of protocol deviations or use of
open-label pharmacological treatment or surgical
ligation (Table 3). This population includes randomised
patients who died before the first ibuprofen dosage was
administered.
Per-protocol population
In the per-protocol population, only patients included
and treated in accordance with the study protocol will
be included. Patients included in the expectant manage-
ment group receiving pharmacological treatment after
fulfilling the open-label criteria will be included in the
per-protocol expectant management group. Patients in
whom other protocol deviations occurred will be ex-
cluded from the per-protocol analysis (Table 3).
Statistical analyses
Patient flow
The flow of trial participants is displayed in the CON-
SORT flow diagram (Fig. 1). As the echocardiographic
screening for the presence of a PDA is common practice
in several of the study sites, while in other centres this is
considered a study procedure, patient flow differs.
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Therefore, informed consent is needed before an echo-
cardiography can be performed as study procedure,
while in case echocardiographic screening is common
practice informed consent can be obtained after echo-
cardiographic assessment for eligibility, as is shown in
Fig.1. Reasons why patients are not eligible, and why eli-
gible patients are not included will be summarized.
Patient characteristics will be collected from all eligible
infants that are not included in this study in order to as-
sess any potential recruitment bias.
The compliance to allocated treatment will be re-
ported for all randomised patients in an additional flow
chart, with reasons why allocated treatment was not
given (Fig. 2).
Table 3 Definition of population analysis sets
Analysis
population





Early pharmacological treatment randomisation:
Including all protocol deviations.
Expectant management randomisation:
Including all protocol deviations.
Per-protocol Early pharmacological treatment randomisation and
treated according to study protocol:
Excluding other protocol deviations.
Expectant management randomisation and treated according to study
protocol:
Including those patients who received ‘open label’ pharmacological
treatment and fulfilled the ‘open label’ criteria as described in the protcol;
Excluding those patients who received ‘open label’ treatment not according
to ‘open label’ criteria in study protocol; Excluding other protocol deviations.
Fig. 1 Consolidated Standards of Reporting Trials (CONSORT) 2010 flow diagram
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Protocol deviations
Protocol deviations are defined as deviations in eligibility
criteria or open-label pharmacological treatment in case
the predefined criteria, as described in the study proto-
col, were not fulfilled. All protocol deviations will be
listed as supplementary material on publication.
Baseline characteristics
We will present the following maternal characteristics:
(a) maternal age; (b) maternal obstetrical disease, divided
in (1) pre-eclampsia; (2) haemolysis, elevated liver en-
zymes and low platelets (HELLP) syndrome; (3) placen-
tal abruption; (4) preterm premature rupture of
membranes (PPROM); and (5) clinical chorioamnionitis,
defined as maternal fever without other cause or pre-
natal antibiotics use without other source of infection
than chorioamnionitis or PPROM; (c) maternal medica-
tion, especially non-steroidal inflammatory drugs (i.e.
ibuprofen and/or indomethacin) and magnesium
sulphate; (d) tocolysis; (e) administration of antenatal
corticosteroids, with incomplete administration defined
as < 48 h or > 14 days before birth; (f) type of delivery,
either vaginally or caesarean section; and (g) multiple
birth (Table 1).
The following baseline characteristics of patients will
be presented: (a) gestational age at birth; (b) birth
weight; (c) outborn; (d) gender; (e) Apgar scores at five
minutes; (f) resuscitation after birth, subdivided in (1)
non-invasive respiratory support; (2) invasive respiratory
support; and (3) circulatory support, defined as the need
for chest compressions and/or epinephrine; (g) respira-
tory distress syndrome; (h) surfactant administration,
and; (i) PDA diameter. All variables will be presented as
summary statistics according to allocation group of the
trial (Table 1).
Continuous normally distributed variables will be sum-
marized with mean and standard deviation. Continuous
non-normally distributed variables will be summarized
using median and interquartile range. Categorical vari-
ables will be summarized using counts and percentages.
Primary outcome
Crude estimates of the relative risk and absolute risk dif-
ference of the primary outcome in the expectant
management group compared with the early pharmaco-
logical treatment group will be calculated. The main
analysis of the effect of expectant management on the
primary outcome will be performed using 95% one sided
Fig. 2 Patient flow of received treatment per treatment allocation group
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confidence interval for the risk difference. Differences in
baseline characteristics are not expected due to random-
isation. In case of an unexpected disbalance in baseline
characteristics correction will be made with appropriate
statistical testing (i.e. logistic regression) if possible.
Short-term secondary outcome
Short-term secondary outcomes will be analysed using a
generalized linear model. Secondary outcomes will be
presented in tables with counts and percentages per
treatment group and presented as absolute risk differ-
ences. No formal adjustments or multiple comparisons
will be made.
Long-term secondary outcome at 2 years corrected age
The key long-term outcome is neurodevelopmental out-
come at 2 years corrected age.
Subgroup analyses
We will perform pre-specified exploratory subgroup ana-
lyses for the primary outcome by examining treatment
and subgroup interaction effects in logistic regression
models. We will perform five analyses, each examining
one subgroup: (a) gestational age groups (less than or
greater or equal to 260/7 weeks), (b) gender (male/fe-
male), (c) multiple pregnancy (yes/no), (d) antenatal cor-
ticosteroids (complete versus incomplete or no antenatal
corticosteroids); and (e) birth weight (less than or
greater or equal to 1000 g).
Sensitivity analyses
For BPD classification, there is uncertainty on how to
categorize continuous positive airway pressure or high-
flow nasal cannula with low or no supplemental oxygen
[27]. The international criteria used will categorize those
infants as having severe BPD [17]. In very premature in-
fants, the reason for this support can be an impaired
control of breathing rather than chronic parenchymal
lung damage. Therefore, infants supported by continu-
ous positive airway pressure or high-flow nasal cannula
in room air will be classified as having mild BPD in an
auxiliary sensitivity analysis in line with the STOP BPD
trial [28].
If possible, we will perform sensitivity analyses on the
primary outcome to investigate the impact of correlation
between infant outcomes within twin or higher-order
multiple births using generalized estimating equations
with a logit link function.
For long-term neurodevelopmental outcome, sensitiv-
ity analyses will be performed (a) using complete cases
only and by applying (b) best-case and (c) worst-case
scenarios for the unobserved neurodevelopmental im-
pairment outcome data.
Differences between the study protocol and statistical
analysis plan
In accordance with the previously published study
protocol [10], we further elaborate on the rationale of
the analyses that will be performed and planned sub-
group as well as sensitivity analyses.
Trial status
Initially, 15 participating centres started recruitment be-
tween December 2016 and April 2019, two additional
centres started recruitment between August 2019 and
May 2020. In another centre no patient was found to be
eligible.
During the study we experienced lower inclusion rates
than expected, both due to a lower rate of parental in-
formed consent, but also a lower rate of PDA > 1.5mm
than anticipated. As the funding by ZonMw stopped on
15 December 2020 and the conflicting DOXA Trial
(Clinicaltrials.gov NCT04430790) started recruitment,
enrollment was ended when in total 273 (48.4% of pro-
jected inclusion) patients were randomized (early
pharmacological treatment n=137; expectant manage-
ment n=136). The power calculation was based on data
from 2008-2012, which might not represent current
data. Even with the actual number of inclusions the
BeNeDuctus Trial is the 3rd largest RCT investigating
PDA treatment since 2000 with regard to the study
population. As the first two largest studies investigated
prophylactic treatment [29, 30], this study is in fact the
largest RCT investigating early pharmacological
treatment.
The last patient is included on 5 December 2020. The
last assessment of the primary outcome will be com-
pleted in March 2021. The last follow-up at 2 years cor-
rected age is expected around March 2023. The database
for the short-term outcome measurements will be
locked only after data has been monitored and this SAP
has been submitted for publication in a peer-reviewed
journal. The long-term outcome measurements will be
locked mid-2023 after monitoring of the data.
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